Latest Upcoming Webinars

Kevin McKernan, CSO at Medicinal Genomics will be joining us to discuss genetic variation in the Psilocybe cubensis synthesis pathway and the design of qPCR assays for simultaneous quantification of E. coli and Salmonella species contamination concurrent with Psilocybe cubensis species identification.

New methods, techniques and efficient data analysis software in liquid chromatography-tandem mass spectrometry (LC-MS/MS) hold the key for accelerating the development of NGBs and increasing their availability.

Antiviral drugs that slow SARS-CoV-2 replication in patient cells are critical for curbing the pandemic. For RNA viruses such as SARS-CoV-2, genome duplication hinges on RNA polymerase, making the enzyme an ideal therapeutic target for drug development.

These technologies can help identify new strategies to enhance myocardial repair and regeneration through target validation and manipulation.

Analysis of SARS-CoV-2-specific T cells is important in understanding their role during acute disease and in long-term protection. Find out about some of the tools used in T-cell research and the promise they show as a cell therapy for COVID-19.

Biopharmaceutical companies are transitioning from the development of standard monoclonal antibody therapies to more intricate antibody structures and new genetic medicines. Not only are these molecules more complex, but scientists are also under tremendous pressure to understand molecular liabilities sooner and close the developability gap in a much shorter time frame.